Decreased HLA-A expression in prostate cancer is associated with normal allele dosage in the majority of cases

Journal of Pathology

Volumn 190, Issue 2, 2000, Pages 169-176

  Lu, Qi Long ^a   Abel, Paul ^a   Mitchell, Stephen ^a   Foster, Christopher ^b   Lalani, El Nasir ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

HLA A; Immunotherapy; Prostate cancer; 2 microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN; HLA A1 ANTIGEN; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALLELE; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE DOSAGE; GENE FREQUENCY; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY;

EID: 0033960984     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1096-9896(200002)190:2<169::aid-path517>3.0.co;2-%23     Document Type: Article

References (27)

1. Daar AS, Fuggle SV, Fabre JW, Ting A, Morris PJ. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984; 38: 287-292.
2. Boon T, De Plaen E, Lurquin C, et al. Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surv 1992; 13: 23-37.
3. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986; 44: 959-968.
4. Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG, Bodmer WF. Tissue typing the HLA-A locus from genomic DNA by sequence-specific PCR: comparison of HLA genotype and surface expression on colorectal tumor cell lines. Proc Natl Acad Sci U S A 1993; 90: 2842-2845.
5. Smith ME, Bodmer JG, Kelly AP, Trowsdale J, Kirkland SC. Bodmer WF. Variation in HLA expression on tumors: an escape from immune response. Cold Spring Harbor Symp Quant Biol 1989; 1: 581-586.
6. Hui K, Grosveld F, Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 1984; 311: 750-752.
7. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumors [see comments]. Proc Natl Acad Sci U S A 1993; 90: 4645-4649.
8. Hui KM, Sim BC, Foo TT, Oei AA. Promotion of tumor growth by transfecting antisense DNA to suppress endogenous H-2Kk MHC gene expression in AKR mouse thymoma. Cell Immunol 1991; 136: 80-94.
9. Pantel K, Schlimok G, Kutter D, et al. Frequent down-regulation of major histocompatibilily class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991; 51: 4712-4715.
10. Cordon Cardo C, Fuks Z, Drobnjak M, Moreno C, Eisenbach L, Feldman M. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 1991; 51: 6372-6380.
11. Concha A, Esteban F, Cabrera T, Ruiz Cabello F, Garrido F. Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 1991; 2: 47-54.
12. Passlick B, Izbicki JR, Simmel S, et al. Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer 1994; 3: 376-381.
13. Passlick B, Pantel K, Kubuschok B, et al. Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. Eur J Cancer 1996; 32a: 141-145.
14. Esteban F, Redondo M, Delgado M, Garrido F, Ruiz Cabello F. MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up. Br J Cancer 1996; 74: 1801-1804.
15. Wintzer HO, Benzing M, von Kleist S. Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas. Br J Cancer 1990; 62: 289-295.
16. Sharpe JC, Abel PD, Gilbertson JA, Brawn P, Foster CS. Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br J Urol 1994; 74: 609-616.
17. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995; 46: 681-686; discussion 686-687.
18. Golding M, Stamp GWH, Oates T, Lalani E-N. Establishment and characterisation of two cell lines derived from a primary adenocarcinoma of the duodenum. J Clin Pathol: Mol Pathol 1996; 49: M33-M39.
19. Dausset J. The major histocompatibility complex in man. Science 1981; 213: 1469-1474.
20. Townsend A. Elliott T, Cerundolo V, Foster L, Barber B, Tse A. Assembly of MHC class I molecules analyzed in vitro [published erratum appears in Cell 1990; 62: following 1233], Cell 1990; 62: 285-295.
21. Bodmer JG, Marsh SG, Albert ED, et al. Nomenclature for factors of the HLA system, 1996. Hum Immunol 1997; 53: 98-128.
22. Ashton Key M, Singh N, Pan LX, Smith ME. HLA antigen expression in enteropathy associated T cell lymphoma. J Clin Pathol 1996; 49: 545-548.
23. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986; 137: 2299-2306.
24. Natali PG, Nicotra MR, Bigotti A, et al. Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A 1989; 86: 6719-6723.
25. Sanda MG, Restifo NP, Walsh JC, et al. Molecular characterization of defective antigen processing in human prostate cancer [see comments]. J Natl Cancer Inst 1995; 87: 280-285.
26. Sokoloff MH, Tso CL, Kaboo R, et al. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 1996; 77: 1862-1872.
27. Bander NH, Yao D, Liu H, et al. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. Prostate 1997; 33: 233-239.